Efforts to target muscarinic acetylcholine receptors in the brain have been hampered by dose limiting side effects. In a tour de force of team science, Brown and colleagues have designed a muscarinic agonist that has been optimized to possess properties that could position it to succeed where other agonists have failed.
展开▼